Danazol for uterine fibroids

Ke Lin, Lin-Qiu Ke, Kun Yang, Chunmei Li, Jing Li, Chun-Mei Li
The Cochrane database of systematic reviews · 2009 · vol. 2011(9) , pp. CD007692 · doi:10.1002/14651858.cd007692.pub2 · PMID:19588442 · PMC7188078 · W1511501229
Systematic review / meta-analysis OA: bronze CC0 ⤵ 5 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

A systematic review found no randomized controlled trials evaluating danazol for uterine fibroids, thus no reliable evidence exists on its benefits or harms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Uterine fibroids (myomas, fibromyomas, leiomyomas) are the most common benign tumours of the female genital tract. Danazol, a synthetic isoxazole derivative chemically related to 17-ethinyl testosterone, has been used for many years for the treatment of women with uterine fibroids. OBJECTIVES: To evaluate the effectiveness and safety of danazol in women with uterine fibroids. SEARCH STRATEGY: We searched the Cochrane Menstrual Disorders and Subfertility Review Group Specialised Register; Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4); MEDLINE; EMBASE; Chinese Biomedical Disc; and the China National Knowledge Infrastructure for relevant trials (to December 2008). Attempts were made to identify trials from references in published studies. We also searched for ongoing trials in the five major clinical trials registries. SELECTION CRITERIA: Randomised controlled trials of danazol versus placebo or any other medical therapy in women with uterine fibroids confirmed by medical procedures, regardless of the women's symptoms or age. Women with malignancies were excluded. DATA COLLECTION AND ANALYSIS: Data extraction and risk of bias assessment were not been performed because there were no identified studies. MAIN RESULTS: We did not identify any studies which met our full inclusion criteria. AUTHORS' CONCLUSIONS: There is no reliable evidence available from randomised controlled trials regarding the benefits and or harms of the use of danazol for treating uterine fibroids.

My notes (saved in your browser only)

MeSH descriptors

Danazol Estrogen Antagonists Leiomyoma Uterine Neoplasms Danazol Estrogen Antagonists Female Humans Leiomyoma Uterine Neoplasms

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (32)

Cited by (5)

Source provenance

openalex
last seen: 2026-05-11T07:16:08.005943+00:00
pubmed
last seen: 2026-10-08T21:06:42.330992+00:00
License: CC0 · commercial use OK